Clinical Trials Directory

Trials / Completed

CompletedNCT04002154

Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV

Ensayo clínico, Aleatorizado, Abierto, de Grupos Paralelos y Con Grupo Control, Para Explorar la Eficacia Del Gel PAPILOCARE en la reparación de la Mucosa cérvico-vaginal Con Lesiones Causadas Por VPH (Ensayo Clínico PALOMA)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
134 (actual)
Sponsor
Procare Health Iberia S.L. · Industry
Sex
Female
Age
30 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV. All the patients included in the study will be Randomized (1:1:1).

Detailed description

Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV. All the patients included in the study will be Randomized (1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm C (usual clinical practice -without treatment-). Selection period of 1 month, followed by randomization and 6 months of treatment followed by a period of another 6 months without treatment. Patients will visit the site into a total of 5 visits throughout the study.

Conditions

Interventions

TypeNameDescription
DEVICEPapilocare vaginal gelPapilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution

Timeline

Start date
2015-10-19
Primary completion
2018-07-31
Completion
2019-02-28
First posted
2019-06-28
Last updated
2021-02-16

Locations

9 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT04002154. Inclusion in this directory is not an endorsement.